GADD45B and plasma cell myeloma: We demonstrated that GADD45β/MKK7-targeting agents are effective in killing multiple myeloma cells, ex vivo and in vivo, and, crucially, are not toxic to healthy tissues, as they preserve the physiological functions of NF-κB [4].